The numbers don’t lie, but they sure as hell don’t tell the whole story. Wildcat Capital Management, the New York outfit that once held 495,606 shares of UroGen Pharma Ltd. (URGN 1.05%), decided the party was over. Filed with the SEC on November 13: a clean break, a $6.79 million exit, and a whisper of dust where conviction once sat.
The stock had pulled a Houdini-up 113% in a year, laughing at the S&P’s meek 15% crawl. UroGen’s market cap swelled to $1.1 billion, a ghost of a thing built on $96.52 million in revenue and a net loss wider than the Grand Canyon. But Wall Street’s circus never rewards the clowns who stay on the tightrope too long.
Wildcat’s new poker hand reads like a noir deck: $123.89 million in ULCC, a desperation bet on RLX at $16.88 million, and pocket change in ALLO, TTAN, and GTLB. Their former stake-4% of assets-now looks like yesterday’s newspaper, ink smudged and headlines forgotten.
Jelmyto, UroGen’s crown jewel, still drips its pyelocalyceal solution into the void. The pipeline advances-UGN-102, UGN-301-with the slow inevitability of a leaky faucet. Their hydrogel tech sticks like gum on a cop’s shoe, promising better drug delivery for cancers that don’t care about promises. The whole operation runs on the biotech equivalent of whiskey and cigarettes: hope, a dash of science, and the quiet understanding that most trials end in tombstones.
Bonderman’s ghost hangs over this play. Wildcat wasn’t built for quick scores-it was a vault for billion-dollar patience. But even patient capital blinks when the lights glare too bright. Selling at the top isn’t a confession; it’s arithmetic with a bloodstained calculator. UroGen’s rally was a moonshot that’d make a gambler blush, but biotech winners rarely move straight. They stagger, zigzag, and leave the weak-kneed in the gutter.
The glossary terms spin like roulette wheels: AUM, TTM, proprietary pipelines. Liquidation isn’t defeat-it’s the house collecting its chips before the table burns down. Exposure’s a funny word when the market’s got knives in its pockets. And “asymmetric upside”? Sounds like a line from a eulogy for a stock that soared too close to the sun.
The silence in the trading room was as loud as a forgotten tomb. 🧠
| Metric | Value |
|---|---|
| Price (as of Friday) | $23.52 |
| Market Capitalization | $1.10 billion |
| Revenue (TTM) | $96.52 million |
| Net Income (TTM) | ($164.64 million) |
Read More
- Spotting the Loops in Autonomous Systems
- Seeing Through the Lies: A New Approach to Detecting Image Forgeries
- Staying Ahead of the Fakes: A New Approach to Detecting AI-Generated Images
- Julia Roberts, 58, Turns Heads With Sexy Plunging Dress at the Golden Globes
- Gold Rate Forecast
- Unmasking falsehoods: A New Approach to AI Truthfulness
- Palantir and Tesla: A Tale of Two Stocks
- Smarter Reasoning, Less Compute: Teaching Models When to Stop
- How to rank up with Tuvalkane – Soulframe
- The Glitch in the Machine: Spotting AI-Generated Images Beyond the Obvious
2025-12-26 21:22